SE523481C2 - Läkemedelskomposition innehållande en HMG-CoA-reduktashämmare och ett organiskt salt med flervärd katjon - Google Patents

Läkemedelskomposition innehållande en HMG-CoA-reduktashämmare och ett organiskt salt med flervärd katjon

Info

Publication number
SE523481C2
SE523481C2 SE0002827A SE0002827A SE523481C2 SE 523481 C2 SE523481 C2 SE 523481C2 SE 0002827 A SE0002827 A SE 0002827A SE 0002827 A SE0002827 A SE 0002827A SE 523481 C2 SE523481 C2 SE 523481C2
Authority
SE
Sweden
Prior art keywords
pharmaceutical composition
composition according
inorganic salt
cation
weight
Prior art date
Application number
SE0002827A
Other languages
English (en)
Swedish (sv)
Other versions
SE0002827D0 (sv
SE0002827L (sv
Inventor
Joseph Richard Creekmore
Norman Alfred Wiggins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE523481(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SE0002827D0 publication Critical patent/SE0002827D0/xx
Publication of SE0002827L publication Critical patent/SE0002827L/xx
Publication of SE523481C2 publication Critical patent/SE523481C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE0002827A 2000-01-26 2000-08-04 Läkemedelskomposition innehållande en HMG-CoA-reduktashämmare och ett organiskt salt med flervärd katjon SE523481C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001621.2A GB0001621D0 (en) 2000-01-26 2000-01-26 Pharmaceutical compositions

Publications (3)

Publication Number Publication Date
SE0002827D0 SE0002827D0 (sv) 2000-08-04
SE0002827L SE0002827L (sv) 2001-07-27
SE523481C2 true SE523481C2 (sv) 2004-04-20

Family

ID=9884259

Family Applications (2)

Application Number Title Priority Date Filing Date
SE0002827A SE523481C2 (sv) 2000-01-26 2000-08-04 Läkemedelskomposition innehållande en HMG-CoA-reduktashämmare och ett organiskt salt med flervärd katjon
SE0002826A SE523471C2 (sv) 2000-01-26 2000-08-04 Läkemedelskomposition innehållande en HMG-CoA- reduktasinhibitor och ett tribasiskt fosfatsalt

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE0002826A SE523471C2 (sv) 2000-01-26 2000-08-04 Läkemedelskomposition innehållande en HMG-CoA- reduktasinhibitor och ett tribasiskt fosfatsalt

Country Status (48)

Country Link
US (2) US6548513B1 (xx)
EP (6) EP1223918B1 (xx)
JP (3) JP3267960B2 (xx)
KR (3) KR100698333B1 (xx)
CN (3) CN100528161C (xx)
AP (2) AP1879A (xx)
AR (3) AR023624A1 (xx)
AT (3) AT412063B (xx)
AU (5) AU6580000A (xx)
BE (2) BE1013414A5 (xx)
BG (4) BG65234B1 (xx)
BR (2) BR0003365A (xx)
CA (3) CA2315141C (xx)
CH (2) CH700184B1 (xx)
CL (1) CL2007001807A1 (xx)
CR (3) CR6568A (xx)
CZ (3) CZ298411B6 (xx)
DE (3) DE10038110B4 (xx)
DK (3) DK1223918T3 (xx)
EE (3) EE05221B1 (xx)
ES (2) ES2155043B1 (xx)
FI (3) FI111806B (xx)
FR (2) FR2795324B1 (xx)
GB (3) GB0001621D0 (xx)
HK (6) HK1036935A1 (xx)
HR (3) HRP20020097B1 (xx)
HU (2) HUP0003111A3 (xx)
IL (4) IL147870A (xx)
IS (3) IS1940B (xx)
IT (2) ITTO20000779A1 (xx)
ME (4) ME00191B (xx)
MY (2) MY123650A (xx)
NL (2) NL1015859C2 (xx)
NO (4) NO327675B1 (xx)
NZ (2) NZ531474A (xx)
PL (2) PL196808B1 (xx)
PT (3) PT102503B (xx)
RS (1) RS50201B (xx)
RU (2) RU2264210C2 (xx)
SE (2) SE523481C2 (xx)
SI (1) SI1223918T1 (xx)
SK (2) SK11792000A3 (xx)
TR (3) TR200201888T2 (xx)
TW (2) TW553749B (xx)
UA (2) UA51853C2 (xx)
WO (2) WO2001054668A1 (xx)
YU (1) YU52902A (xx)
ZA (2) ZA200003997B (xx)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
ES2401598T3 (es) † 2000-04-10 2013-04-22 Teva Pharmaceutical Industries, Ltd. Composiciones farmacéuticas estables que contienen ácidos 7-sustituido-3,5-dihidroxiheptanoicos o ácidos 7-sustituido-3,5-dihidroxiheptenoicos
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
GB0028429D0 (en) * 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7883721B2 (en) * 2001-01-30 2011-02-08 Smithkline Beecham Limited Pharmaceutical formulation
US20050175687A1 (en) * 2001-01-30 2005-08-11 Mcallister Stephen M. Pharmaceutical formulations
US7842308B2 (en) * 2001-01-30 2010-11-30 Smithkline Beecham Limited Pharmaceutical formulation
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
JPWO2004016262A1 (ja) * 2002-08-12 2005-12-02 協和醗酵工業株式会社 アミノ酸含有チュアブル錠
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
ES2655435T3 (es) * 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) * 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) * 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
CA2565667C (en) * 2004-05-04 2013-10-29 Lewis Roe Hendricks Directly compressible tricalcium phosphate
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
CN1323665C (zh) * 2004-06-16 2007-07-04 鲁南制药集团股份有限公司 治疗高血脂症的组合物
JP2007508379A (ja) * 2004-07-13 2007-04-05 テバ ファーマシューティカル インダストリーズ リミティド Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法
SG155189A1 (en) * 2004-08-06 2009-09-30 Transform Pharmaceuticals Inc Novel fenofibrate formulations and related methods of treatment
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
CA2591439C (en) * 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
CN101500555A (zh) * 2005-08-04 2009-08-05 变换药品公司 包含非诺贝特和他汀的新型制剂及相关治疗方法
WO2007022488A2 (en) * 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
DK1944029T3 (da) * 2005-10-31 2012-01-23 Kowa Co Farmaceutisk præparat med fremragende fotostabilitet
CN101330919B (zh) * 2005-12-20 2012-12-05 力奇制药公司 包含(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲磺酰基)氨基]嘧啶-5-基]-(3r,5s)-3,5-二羟基庚-6-烯酸的药物组合物
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
ES2564250T3 (es) * 2006-05-03 2016-03-21 Msn Laboratories Private Limited Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
HUE028475T2 (en) * 2006-10-09 2016-12-28 Msn Laboratories Private Ltd A novel process for the preparation of statins and their pharmaceutically acceptable salts
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CN101336920B (zh) * 2007-07-05 2013-06-05 江苏正大天晴药业股份有限公司 一种稳定的药物组合物
AU2009208610A1 (en) * 2008-01-30 2009-08-06 Lupin Limited Modified release formulations of HMG CoA reductase inhibitors
WO2009112870A1 (en) * 2008-03-11 2009-09-17 Belupo-Lijekovi I Kozmetika D.D. Pharmaceutical composition comprising rosuvastatin calcium and magnesium carbonate hydroxide pentahydrate as a stabilizer
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
WO2009150228A2 (en) * 2008-06-13 2009-12-17 Glaxo Group Limited Pharmaceutical formulations
EP2138165A1 (en) 2008-06-27 2009-12-30 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising a statin
SI2309992T1 (en) * 2008-06-27 2018-03-30 Krka, Tovarna Zdravil, D.D., Novo Mesto A pharmaceutical composition comprising a statin
BRPI0822782A2 (pt) * 2008-06-27 2015-09-29 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi composição farmacêutica que compreende rosuvastatina
PL386051A1 (pl) * 2008-09-09 2010-03-15 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Stabilna doustna kompozycja farmaceutyczna zawierająca farmaceutycznie dopuszczalną sól kwsu [(E)-7-[4-(4-fluorofenylo)-6-izopropylo-2-[metylo(metylosulfonylo)amino]pirymidyn-5-ylo] (3R,5S)-3,5-dihydroksyhept-6-enowego
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
MX344885B (es) * 2008-11-10 2017-01-10 Psicofarma S A De C V Proceso para la obtencion de una composicion de rosuvastatina calcica y producto obtenido.
WO2010089770A2 (en) 2009-01-19 2010-08-12 Msn Laboratories Limited Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof
TR200902077A2 (tr) 2009-03-17 2010-01-21 Sanovel İlaç San.Veti̇c.A.Ş. Stabil rosuvastatin kompozisyonları
US8470805B2 (en) * 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
TR200904341A2 (tr) 2009-06-03 2010-12-21 Bi̇lgi̇ç Mahmut Rosuvastatin kalsiyum içeren kararlı farmasötik bileşimler.
EP2464344A2 (en) 2009-08-13 2012-06-20 Synthon B.V. Pharmaceutical tablet comprising rosuvastatin calcium
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
CN101766578B (zh) * 2010-02-09 2011-06-08 鲁南贝特制药有限公司 一种含瑞舒伐他汀钙的片剂及其制备工艺
EP2566465A2 (en) 2010-05-04 2013-03-13 Mahmut Bilgic Stable rosuvastatin formulations
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물
RU2508109C2 (ru) * 2011-05-27 2014-02-27 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения нарушений липидного обмена
US10952968B2 (en) * 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
KR20140111982A (ko) * 2013-03-12 2014-09-22 주식회사 엘지생명과학 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법
RO129060B1 (ro) 2013-04-25 2014-11-28 Antibiotice S.A. Compoziţie farmaceutică stabilă cu rosuvastatină calcică amorfă
RU2547574C2 (ru) * 2013-07-09 2015-04-10 Общество с ограниченной ответственностью "Трейдсервис" Лекарственная форма гиполипидемического действия и способ ее изготовления
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
WO2016076280A1 (ja) * 2014-11-11 2016-05-19 塩野義製薬株式会社 光に対して不安定な薬物を含有する多層錠剤
JP2016169198A (ja) * 2015-03-13 2016-09-23 大原薬品工業株式会社 ロスバスタチンカルシウムを含有する錠剤
JP6095176B2 (ja) * 2015-04-24 2017-03-15 大原薬品工業株式会社 ロスバスタチンカルシウムの光安定性が向上したフィルムコーティング錠剤
WO2017070612A1 (en) 2015-10-23 2017-04-27 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
EP3243506A1 (en) 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition
CN110022861A (zh) 2016-09-30 2019-07-16 林德拉有限公司 用于金刚烷类药物缓释的胃驻留系统
CN107913257A (zh) * 2016-10-10 2018-04-17 北京阜康仁生物制药科技有限公司 一种包含瑞舒伐他汀钙的药物组合物及其制备方法
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
JP2018027987A (ja) * 2017-11-24 2018-02-22 共和薬品工業株式会社 医薬組成物
CN112274487A (zh) * 2019-07-25 2021-01-29 北京福元医药股份有限公司 一种瑞舒伐他汀钙药物制剂
CN110638743B (zh) * 2019-10-25 2023-03-28 乐普制药科技有限公司 一种含布立西坦的组合物
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2262229A (en) * 1939-06-24 1941-11-11 Interchem Corp Pigment and method of preparation
GB653026A (en) 1947-07-02 1951-05-09 Merck & Co Inc Vitamin preparations
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4929620A (en) * 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
NO890521L (no) 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
US5004651A (en) 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
DK0475482T3 (da) 1990-09-13 1995-04-03 Akzo Nobel Nv Stabiliserede faste kemiske midler
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
EP0680320B1 (en) 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
PL186907B1 (pl) 1995-12-22 2004-03-31 Kowa Co Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
BR9910947A (pt) 1998-06-05 2001-03-06 Warner Lambert Co Estabilização de composições que contêm inibidores de ace utilizando óxido de magnésio
SI20109A (sl) 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
US6150410A (en) 1999-02-04 2000-11-21 Abbott Laboratories pH independent extended release pharmaceutical formulation
AR022462A1 (es) * 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0000710D0 (en) * 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1253921A4 (en) 2000-01-28 2004-10-13 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS

Also Published As

Publication number Publication date
CA2313783C (en) 2002-03-12
ES2155043B1 (es) 2001-12-01
HU222578B1 (hu) 2003-08-28
IS1940B (is) 2004-07-16
HK1048950A1 (zh) 2003-04-25
HK1200368A1 (en) 2015-08-07
CR10114A (es) 2008-08-21
TWI228050B (en) 2005-02-21
EE05221B1 (et) 2009-10-15
IL147870A (en) 2003-10-31
TW553749B (en) 2003-09-21
HK1040936B (zh) 2010-06-11
CZ298411B6 (cs) 2007-09-26
FI20001750A (fi) 2001-07-27
KR100388713B1 (ko) 2003-06-25
DE60001371T2 (de) 2004-01-22
SE0002826L (sv) 2001-07-27
SK11782000A3 (sk) 2001-12-03
NO20003967L (no) 2001-07-27
BG106926A (bg) 2003-04-30
DK200001170A (da) 2001-01-27
ATA13612000A (de) 2004-02-15
AU738074B2 (en) 2001-09-06
IL150513A (en) 2012-12-31
CZ20002884A3 (cs) 2001-09-12
ES2171123A1 (es) 2002-08-16
DE10038108A1 (de) 2001-08-02
EP1251831A1 (en) 2002-10-30
CZ290167B6 (cs) 2002-06-12
PT102503A (pt) 2000-12-29
CN1319396A (zh) 2001-10-31
SE523471C2 (sv) 2004-04-20
FR2795324B1 (fr) 2002-05-17
EP2133070A1 (en) 2009-12-16
RU2264210C2 (ru) 2005-11-20
ZA200003997B (en) 2000-08-14
RS50201B (sr) 2009-07-15
CA2315141C (en) 2009-08-18
GB0019029D0 (en) 2000-09-27
FR2804025A1 (fr) 2001-07-27
JP3267960B2 (ja) 2002-03-25
AR023624A1 (es) 2002-09-04
ITTO20000779A0 (it) 2000-08-04
AT412062B (de) 2004-09-27
CZ20002883A3 (cs) 2000-10-11
DK200001171A (da) 2001-07-27
TR200201888T2 (tr) 2002-11-21
BG66159B1 (bg) 2011-09-30
GB0019028D0 (en) 2000-09-27
NO20003968D0 (no) 2000-08-04
SE0002827D0 (sv) 2000-08-04
RU2002122752A (ru) 2004-03-10
YU5202A (sh) 2004-12-31
TR200200270T2 (tr) 2002-06-21
IL187416A0 (en) 2008-02-09
JP2001206847A (ja) 2001-07-31
BG106393A (en) 2002-07-31
WO2001054669A1 (en) 2001-08-02
EE05586B1 (et) 2012-10-15
KR20010077840A (ko) 2001-08-20
AU781269C (en) 2006-11-30
FI20001749A (fi) 2001-07-27
HU0003110D0 (en) 2000-10-28
HUP0003111A3 (en) 2003-03-28
CR6687A (es) 2005-07-18
IS6480A (is) 2002-07-23
CA2639407C (en) 2011-09-13
MEP33708A (en) 2010-10-10
FI121589B (fi) 2011-01-31
GB2358583A (en) 2001-08-01
HRP20020632B1 (en) 2010-12-31
DE10038110A1 (de) 2001-08-23
HRP20080525A2 (en) 2008-12-31
HRP20020097B1 (en) 2010-12-31
JP4800467B2 (ja) 2011-10-26
CA2639407A1 (en) 2001-07-26
AU6580000A (en) 2001-08-07
CH700184B1 (de) 2010-07-15
IL150513A0 (en) 2003-02-12
HK1036934A1 (en) 2002-01-25
NZ531474A (en) 2007-04-27
BR0003365A (pt) 2001-09-18
HU0003111D0 (en) 2000-10-28
HRP20020632A2 (en) 2004-12-31
PL341855A1 (en) 2001-07-30
CN1149997C (zh) 2004-05-19
FR2804025B1 (fr) 2002-08-23
EP1223918B1 (en) 2003-02-05
GB2358582A (en) 2001-08-01
EE200200052A (et) 2003-04-15
JP4800988B2 (ja) 2011-10-26
AP2002002591A0 (en) 2002-09-30
IS6254A (is) 2002-01-29
HK1036935A1 (en) 2002-01-25
ATE232088T1 (de) 2003-02-15
PT1223918E (pt) 2003-06-30
SK11792000A3 (sk) 2001-12-03
AU781269B2 (en) 2005-05-12
ATA13602000A (de) 2004-02-15
HK1040936A1 (en) 2002-06-28
AR060248A2 (es) 2008-06-04
DK178242B1 (da) 2015-09-28
AP2002002409A0 (en) 2002-03-31
EE200900047A (et) 2011-04-15
DE60001371D1 (de) 2003-03-13
CA2315141A1 (en) 2001-07-26
GB2358582B (en) 2004-09-29
NO2010005I1 (no) 2010-05-03
EE04990B1 (et) 2008-04-15
CN1282581A (zh) 2001-02-07
ME00202B (me) 2010-10-10
ME00191B (me) 2010-10-10
AR025055A1 (es) 2002-11-06
FR2795324A1 (fr) 2000-12-29
NO312434B1 (no) 2002-05-13
UA77156C2 (en) 2006-11-15
KR100698333B1 (ko) 2007-03-23
EE200200411A (et) 2003-12-15
SE0002826D0 (sv) 2000-08-04
FI20105657A (fi) 2010-06-10
AP1449A (en) 2005-07-28
EP2018853A1 (en) 2009-01-28
AP1879A (en) 2008-08-14
AT412063B (de) 2004-09-27
SE0002827L (sv) 2001-07-27
ZA200003998B (en) 2000-08-14
CN100528161C (zh) 2009-08-19
BG66168B1 (bg) 2011-10-31
NO327675B1 (no) 2009-09-07
AU2000264559A1 (en) 2001-08-07
NO20071303L (no) 2001-07-27
PT102503B (pt) 2004-02-27
NO327554B1 (no) 2009-08-10
BR0003364A (pt) 2001-09-18
CN101028268A (zh) 2007-09-05
AU5184100A (en) 2001-08-02
ITTO20000779A1 (it) 2002-02-04
CR6568A (es) 2004-03-05
IS2805B (is) 2012-09-15
FI111806B (fi) 2003-09-30
BG65234B1 (bg) 2007-09-28
AU5184200A (en) 2001-08-02
HUP0003111A2 (hu) 2002-02-28
PL341853A1 (en) 2001-01-29
BE1013413A3 (fr) 2001-12-04
TR200701171T2 (tr) 2007-04-24
AU2005202392C1 (en) 2016-06-02
HUP0003110A3 (en) 2003-02-28
EP2266540A1 (en) 2010-12-29
SI1223918T1 (en) 2003-06-30
BG110353A (en) 2009-09-30
YU52902A (sh) 2006-01-16
FI20001749A0 (fi) 2000-08-04
IS8620A (is) 2007-03-07
PT102504A (pt) 2001-07-31
IL147870A0 (en) 2002-08-14
NZ519774A (en) 2004-04-30
FI20001750A0 (fi) 2000-08-04
US6548513B1 (en) 2003-04-15
KR20030036492A (ko) 2003-05-09
GB2358583B (en) 2002-02-06
BE1013414A5 (fr) 2001-12-04
SK283872B6 (sk) 2004-03-02
DE10038110B4 (de) 2006-06-29
PL196808B1 (pl) 2008-02-29
NO20003967D0 (no) 2000-08-04
DK1223918T3 (da) 2003-04-28
JP2007182452A (ja) 2007-07-19
ES2155043A1 (es) 2001-04-16
HRP20020097A2 (en) 2002-06-30
US6316460B1 (en) 2001-11-13
WO2001054668A1 (en) 2001-08-02
JP2001206877A (ja) 2001-07-31
HUP0003110A2 (hu) 2001-05-28
HK1047052A1 (zh) 2003-02-07
CH691347A5 (de) 2001-07-13
ITTO20000780A1 (it) 2000-11-04
ES2171123B1 (es) 2003-11-16
CL2007001807A1 (es) 2008-01-18
CZ299105B6 (cs) 2008-04-23
MY123650A (en) 2006-05-31
MY122707A (en) 2006-04-29
NO20003968L (no) 2001-07-27
FI121365B (fi) 2010-10-29
AU2005202392B2 (en) 2008-11-20
AU2005202392A1 (en) 2005-06-30
CA2313783A1 (en) 2000-10-16
NL1015858C2 (nl) 2001-07-27
EP1223918A1 (en) 2002-07-24
NL1015859C2 (nl) 2001-10-16
NL1015859A1 (nl) 2001-07-27
EP2774609A1 (en) 2014-09-10
KR20000072135A (ko) 2000-12-05
GB0001621D0 (en) 2000-03-15
UA51853C2 (uk) 2002-12-16
MEP33808A (en) 2010-10-10
RU2206324C1 (ru) 2003-06-20

Similar Documents

Publication Publication Date Title
SE523481C2 (sv) Läkemedelskomposition innehållande en HMG-CoA-reduktashämmare och ett organiskt salt med flervärd katjon
MXPA00007659A (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
NUG Patent has lapsed